← Leaderboards
Iman Osman
New York University School Of Medicine
$8,470,073
Attributed
$10,568,176
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.1M · FY2013–25$10M$7.5M$5M$2.5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,579,322 · 12
By mechanism
P50$15,983,150 · 3
U54$7,658,454 · 2
R01$4,196,206 · 2
R21$1,578,426 · 4
P30$163,086 · 1
Top collaborators
- Jeffrey S Weber12 shared
- Eva Hernando10 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Seth J. Orlow$11,704,418
- Maarten C Bosland$10,491,195
- Andre Luis Moreira$1,459,624
- Jill P Buyon$29,367,681
Others in their field
Top investigators on “Melanoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
- Richard L Schilsky · University Of Chicago$108,377,382
- Larry Arthur$59,113,709
- Charles A Coltman · Southwest Oncology Group$55,198,633
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
- Meenhard Herlyn · University Of Pennsylvania$46,448,742
Research focus
MelanomaProgramsTumorResearch PersonnelResourcesCollaborationsInstitutionMalignant NeoplasmsMolecularClinical TrialsPredictive MarkerProspectiveTranslational ResearchInnovationInfrastructureResearch Project GrantsResponseMouse ModelAdjuvantTissuesMetastatic MelanomaResectedCareerImmune
Grant awards (53)
NYULH Metastasis Research Network Center (NYULH MetNet Center)$1,530,347
U54 · FY2025 · CA
NYU Melanoma SPORE$1,230,080
P50 · FY2025 · CA · contact PI
Core B - Biospecimen/Pathology Core$331,689
P50 · FY2025 · CA · contact PI
Core 1: Clinicopathological Analysis and Disease Modeling$255,058
U54 · FY2025 · CA · contact PI
Admin Core$197,147
P50 · FY2025 · CA · contact PI
NYULH Metastasis Research Network Center (NYULH MetNet Center)$1,603,811
U54 · FY2024 · CA
NYU Melanoma SPORE$896,274
P50 · FY2024 · CA · contact PI
Core 1: Clinicopathological Analysis and Disease Modeling$252,415
U54 · FY2024 · CA · contact PI
Admin Core$182,271
P50 · FY2024 · CA · contact PI
Core B - Biospecimen/Pathology Core$127,398
P50 · FY2024 · CA · contact PI
NYU Melanoma SPORE$2,084,236
P50 · FY2023 · CA · contact PI
NYULH Metastasis Research Network Center (NYULH MetNet Center)$1,654,459
U54 · FY2023 · CA
Core 1: Clinicopathological Analysis and Disease Modeling$356,808
U54 · FY2023 · CA · contact PI
Admin Core$280,990
P50 · FY2023 · CA · contact PI
Core B - Biospecimen/Pathology Core$234,665
P50 · FY2023 · CA · contact PI
NYULH Metastasis Research Network Center - Admin Supplement$50,850
U54 · FY2023 · CA
Melanoma (MEL) Research Program$32,775
P30 · FY2023 · CA · contact PI
NYU Melanoma SPORE$2,035,150
P50 · FY2022 · CA · contact PI
NYULH Metastasis Research Network Center (NYULH MetNet Center)$1,688,223
U54 · FY2022 · CA
(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition$360,682
R01 · FY2022 · CA · contact PI
Admin Core$282,527
P50 · FY2022 · CA · contact PI
Core 1: Clinicopathological Analysis and Disease Modeling$266,483
U54 · FY2022 · CA · contact PI
Core B - Biospecimen/Pathology Core$250,991
P50 · FY2022 · CA · contact PI
Novel targets of treatment for NF1-mutant melanoma$194,142
R21 · FY2022 · CA · contact PI
Melanoma (MEL) Research Program$32,775
P30 · FY2022 · CA · contact PI
NYU Melanoma SPORE$2,065,182
P50 · FY2021 · CA · contact PI
(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition$495,996
R01 · FY2021 · CA · contact PI
Admin Core$282,526
P50 · FY2021 · CA · contact PI
Core B - Biospecimen/Pathology Core$250,990
P50 · FY2021 · CA · contact PI
Novel targets of treatment for NF1-mutant melanoma$237,724
R21 · FY2021 · CA · contact PI
Melanoma (MEL) Research Program$32,775
P30 · FY2021 · CA · contact PI
NYU Melanoma SPORE$2,109,068
P50 · FY2020 · CA · contact PI
(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition$566,338
R01 · FY2020 · CA · contact PI
Admin Core$288,601
P50 · FY2020 · CA · contact PI
Core B - Biospecimen/Pathology Core$256,386
P50 · FY2020 · CA · contact PI
Melanoma (MEL) Research Program$32,500
P30 · FY2020 · CA · contact PI
NYU Melanoma SPORE$2,063,466
P50 · FY2019 · CA · contact PI
(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition$543,889
R01 · FY2019 · CA · contact PI
Admin Core$282,524
P50 · FY2019 · CA · contact PI
Core B - Biospecimen/Pathology Core$250,989
P50 · FY2019 · CA · contact PI
Melanoma (MEL) Research Program$32,261
P30 · FY2019 · CA · contact PI
(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition$481,288
R01 · FY2018 · CA · contact PI
A germline variant that predicts and modulates the response of melanoma to immunotherapy$237,724
R21 · FY2018 · CA · contact PI
Prognostic and Functional Role of microRNAs in Melanoma Brain Metastasis$351,713
R01 · FY2017 · CA
A germline variant that predicts and modulates the response of melanoma to immunotherapy$198,103
R21 · FY2017 · CA · contact PI
Prognostic and Functional Role of microRNAs in Melanoma Brain Metastasis$351,713
R01 · FY2016 · CA
Development of a new treatment modality for melanoma brain metastases - Resubmission - 1$169,500
R21 · FY2016 · CA · contact PI
Prognostic and Functional Role of microRNAs in Melanoma Brain Metastasis$351,713
R01 · FY2015 · CA
Development of a new treatment modality for melanoma brain metastases - Resubmission - 1$203,400
R21 · FY2015 · CA · contact PI
Prognostic and Functional Role of microRNAs in Melanoma Brain Metastasis$341,161
R01 · FY2014 · CA
Prognostic and Functional Role of microRNAs in Melanoma Brain Metastasis$351,713
R01 · FY2013 · CA
Clin.Relevance of Circulat.Tumor Cells in Bladder Cancer$169,000
R21 · FY2004 · CA
Clin.Relevance of Circulat.Tumor Cells in Bladder Cancer$168,833
R21 · FY2003 · CA